<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671251</url>
  </required_header>
  <id_info>
    <org_study_id>AEVI-007-MM-101</org_study_id>
    <nct_id>NCT04671251</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aevi Genomic Medicine, LLC, a Cerecor company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecor Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects&#xD;
      with relapsed or refractory Multiple Myeloma.&#xD;
&#xD;
      The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics&#xD;
      of AEVI-007.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose</measure>
    <time_frame>Cohorts 1-3 will take approximately 4-5 months</time_frame>
    <description>Identify the recommended Phase 2 dose based on safety, pharmacokinetics and pharmacodynamics observed in this Phase 1b study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant Changes in Clinical Laboratory Results</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant Changes in Electrocardiogram Recordings</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant Changes to Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clinically Significant Changes in Physical Examination Findings</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration of AEVI-007</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life of AEVI-007</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of AEVI-007</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of AEVI-007</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to Time t of AEVI-007</measure>
    <time_frame>Approximately 9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-myeloma activity</measure>
    <time_frame>Approximately 9 months</time_frame>
    <description>To assess the anti-myeloma activity of AEVI-007 based on International Myeloma Working Group (IMWG) criteria for response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of ADAs</measure>
    <time_frame>Approximately 9 months</time_frame>
    <description>To determine the incidence of anti-drug antibodies to AEVI-007.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Approximately 9 months</time_frame>
    <description>Defined as the time from start of the treatment to the first observation of PR or better. TTR is restricted to only subjects with confirmed responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Approximately 9 months</time_frame>
    <description>Defined as the duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 9 months</time_frame>
    <description>Defined as the duration from the first observation of PR to the time of disease progression, with deaths from causes other than progression censored</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>AEVI-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEVI-007</intervention_name>
    <description>50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.</description>
    <arm_group_label>AEVI-007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has active R/R multiple myeloma.&#xD;
&#xD;
          2. Subject has measurable myeloma based on any of the following:&#xD;
&#xD;
               -  Serum M-protein &gt; 0.5 g/dL&#xD;
&#xD;
               -  Urine M-protein &gt; 200 mg/24 hours&#xD;
&#xD;
               -  Serum free light chains &gt; 10 mg/dL&#xD;
&#xD;
               -  Measurable plasmacytoma or extramedullary disease&#xD;
&#xD;
          3. Subject has active myeloma despite prior therapy with a proteasome inhibitor, an&#xD;
             immunomodulatory agent and an anti-CD38 antibody.&#xD;
&#xD;
             Note: Subject must not be a candidate for regimens known to provide clinical benefit.&#xD;
&#xD;
          4. Subject has an Eastern Cooperative Oncology Group performance status (ECOG PS) score&#xD;
             of 0 or 1.&#xD;
&#xD;
          5. Subject is &gt; 18 years of age.&#xD;
&#xD;
          6. Subject has adequate hematopoietic, renal and hepatic function, defined as:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,000/μL; platelet count &gt; 75,000/μL in patients with&#xD;
                  &lt; 50% marrow involvement&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 750/μL; platelet count &gt; 50,000/μL in patients with&#xD;
                  &gt;50% marrow involvement&#xD;
&#xD;
               -  Serum creatinine &lt; 2.5 mg/dL or calculated creatinine clearance of &gt; 30 mL/min&#xD;
                  according to the Cockcroft-Gault equation&#xD;
&#xD;
               -  Aspartate transaminase/alanine transaminase ≤2.5× the upper limit of normal (ULN)&#xD;
                  and total bilirubin &lt; 2× the ULN&#xD;
&#xD;
          7. If applicable, the subject has undergone prior autologous hematopoietic stem cell&#xD;
             transplantation more than 100 days prior to the Screening Visit.&#xD;
&#xD;
          8. Female patients of childbearing potential who are heterosexually active and male&#xD;
             patients with female sexual partners of childbearing potential must agree to use an&#xD;
             effective method of contraception (eg, oral contraceptives, double-barrier methods&#xD;
             such as a condom and a diaphragm, intrauterine device) or abstain from sexual activity&#xD;
             during the study and for 220 days (5 half-lives) following the last dose of study&#xD;
             medication, or to abstain from sexual intercourse for this duration of study&#xD;
             participation. A woman not of childbearing potential is one who has undergone&#xD;
             bilateral oophorectomies or who is post-menopausal, defined as the absence of&#xD;
             menstrual periods for 12 consecutive months.&#xD;
&#xD;
          9. Subject has provided written informed consent for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has currently active infection requiring use of systemic antimicrobial&#xD;
             therapy.&#xD;
&#xD;
          2. Subject has received corticosteroids (&gt;10 mg/daily prednisone or equivalent) or&#xD;
             chemotherapy within 2 weeks of study drugs (4 weeks for nitrosourea, melphalan or&#xD;
             monoclonal antibodies).&#xD;
&#xD;
          3. Subject has hyperviscosity syndrome.&#xD;
&#xD;
          4. Subject has central nervous system involvement by myeloma, including leptomeningeal&#xD;
             involvement.&#xD;
&#xD;
          5. Subject is judged to be at risk for impending fracture.&#xD;
&#xD;
          6. Subject has known amyloidosis or POEMS (Polyneuropathy, Organomegaly, Endocrinopathy,&#xD;
             Monoclonal protein, Skin changes) syndrome.&#xD;
&#xD;
          7. Subject had another malignancy within 1 year of study entry with high probability of&#xD;
             recurrence.&#xD;
&#xD;
          8. Subject is pregnant or lactating.&#xD;
&#xD;
          9. Subject has a history of, or tests positive for, hepatitis B, untreated hepatitis C or&#xD;
             human immunodeficiency virus (HIV). Subject with hepatitis C who has received a full&#xD;
             course of anti-viral therapy or who is currently receiving anti-viral therapy with&#xD;
             undetectable levels of hepatitis C RNA is eligible for the trial.&#xD;
&#xD;
         10. Subject has undergone major surgery or trauma within 4 weeks of study entry.&#xD;
&#xD;
         11. Subject has been previously treated with an anti IL 18 antibody.&#xD;
&#xD;
         12. Subject is currently taking immunomodulatory drugs, including pharmacologic doses of&#xD;
             systemic glucocorticoids (&gt; 10 mg prednisone daily or equivalent), anti tumor necrosis&#xD;
             factor alpha (TNFα) antibodies, anti-IL-17 antibodies, anti IL 12/23 antibodies,&#xD;
             phosphodiesterase-4 (PDE-4) inhibitors, janus kinase (JAK) inhibitors, IL-6&#xD;
             inhibitors, rituximab, methotrexate, cyclosporine, mycophenolate.&#xD;
&#xD;
         13. Subject with known active autoimmune disorders including, but not limited to,&#xD;
             rheumatoid arthritis, lupus, systemic sclerosis, Sjogren's syndrome, psoriatic&#xD;
             arthritis, ulcerative colitis, Crohn's disease, vasculitis, multiple sclerosis.&#xD;
             Subjects with autoimmune endocrinopathies on stable doses of replacement hormone&#xD;
             therapy are eligible for the trial.&#xD;
&#xD;
         14. Subject has had a prior allogeneic transplant.&#xD;
&#xD;
         15. Subject has New York Heart Association (NYHA) Class III or IV Congestive Heart Failure&#xD;
             (CHF), myocardial infarction or acute coronary syndrome within 6 months prior to the&#xD;
             Screening Visit, ongoing angina pectoris, severe peripheral vascular disease, or any&#xD;
             other concomitant medical disorder that might interfere with the subject's&#xD;
             participation in the trial or interpretation of the study data.&#xD;
&#xD;
         16. Subject has psychiatric, substance abuse or social conditions that would interfere&#xD;
             with the subject's participation or cooperation with the requirements of the trial.&#xD;
&#xD;
         17. Subject has known hypersensitivity to any of the components of AEVI-007.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>H. Jeffrey Wilkins, MD</last_name>
    <phone>610-457-5095</phone>
    <email>jwilkins@cerecor.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>James R. Berenson, MD., Inc.</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

